Saturday - April 26, 2025
SCOTTSDALE, Ariz., May 23, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will participate in the following upcoming investor conferences.
UBS Healthcare Services Cape Cod Summit
Participants: Dave Bourdon, CFO, and Monica Prokocki, VP of Finance and Investor Relations
Date: Tuesday, June 4, 2024
Location: Chatham Bars Inn, Chatham, MA
Note: No presentation due to event format; investor meetings only
Goldman Sachs 45th Annual Healthcare Conference
Presenters: Dave Bourdon, CFO, and Monica Prokocki, VP of Finance and Investor Relations
Date: Monday, June 10, 2024
Location: Loews Miami Beach Hotel, Miami Beach, FL
Time: 10:00 a.m. (Eastern time)
Moderated by: Jamie Perse
If applicable, the presentation will be webcast live, and a replay will be made available following the event, on the Investor Relations section of LifeStance’s website at https://investor.lifestance.com.
About LifeStance Health
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ approximately 6,800 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
Last Trade: | US$6.53 |
Daily Change: | 0.04 0.62 |
Daily Volume: | 913,813 |
Market Cap: | US$2.500B |
February 27, 2025 February 27, 2025 November 20, 2024 November 07, 2024 August 21, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load